Xience implantation followed by short dual antiplatelet therapy: ‘the new normal’?

Niels M.R. van der Sangen, Wouter J. Kikkert, José P.S. Henriques, Bimmer E.P.M. Claessen

Research output: Contribution to journalEditorial

Abstract

The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalHeart International
Volume15
Issue number2
StatePublished - 2021
Externally publishedYes

Keywords

  • Aspirin
  • Drug-eluting stents
  • Dual anti-platelet therapy
  • High bleeding risk
  • P2Y12 inhibitor
  • Percutaneous coronary intervention
  • XIENCE stent

Fingerprint

Dive into the research topics of 'Xience implantation followed by short dual antiplatelet therapy: ‘the new normal’?'. Together they form a unique fingerprint.

Cite this